Isatuximab SAR650984
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Autoimmune Hemolytic Anemia (wAIHA)
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Trial Timeline
Sep 9, 2021 → Jun 26, 2023
NCT ID
NCT04661033About Isatuximab SAR650984
Isatuximab SAR650984 is a phase 2 stage product being developed by Sanofi for Warm Autoimmune Hemolytic Anemia (wAIHA). The current trial status is terminated. This product is registered under clinical trial identifier NCT04661033. Target conditions include Warm Autoimmune Hemolytic Anemia (wAIHA).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04661033 | Phase 2 | Terminated |
| NCT03733717 | Phase 1 | Completed |
| NCT02812706 | Phase 1/2 | Completed |
Competing Products
12 competing products in Warm Autoimmune Hemolytic Anemia (wAIHA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly | Immunovant | Phase 2 | 49 |
| HMPL-523(300mg PO QD) + Placebo | HUTCHMED | Phase 2/3 | 60 |
| APL-2 | Apellis Pharmaceuticals | Phase 2 | 47 |
| Obexelimab + Obexelimab | Zenas BioPharma | Phase 3 | 72 |
| ANX005 | Annexon | Phase 2 | 47 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |
| Fostamatinib disodium + Placebo | Rigel Pharmaceuticals | Phase 3 | 69 |